Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)
Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study
Aim(s): However, there is relatively limited literature regarding factors that affect progression-free survival(PFS) in NET patients receiving this treatment and we aimed to investigate this further
Materials and methods: Retrospective analysis of 245 treatment-naïve patients with advanced NETs treated with LA(as monotherapy) in our centre. PFS was calculated for the entire cohort. Demographic, clinical and biochemical data were collected. Univariate(UVA) and multivariate(MVA) analyses were performed to determine factors affecting PFS
Conference: 15th Annual ENETSConcerence (2018)
To read the full abstract, please log into your ENETS Member account.